- Home
- AEYE vs CTNM Comparison
AEYE vs CTNM Comparison
Compare AEYE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- CTNM
- Stock Information
- Founded
- AEYE 2005
- CTNM 2009
- Country
- AEYE United States
- CTNM United States
- Employees
- AEYE N/A
- CTNM N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- CTNM
- Sector
- AEYE Technology
- CTNM
- Exchange
- AEYE Nasdaq
- CTNM Nasdaq
- Market Cap
- AEYE 138.0M
- CTNM 114.1M
- IPO Year
- AEYE N/A
- CTNM 2024
- Fundamental
- Price
- AEYE $12.46
- CTNM $3.87
- Analyst Decision
- AEYE Strong Buy
- CTNM Strong Buy
- Analyst Count
- AEYE 5
- CTNM 4
- Target Price
- AEYE $26.40
- CTNM $23.75
- AVG Volume (30 Days)
- AEYE 117.6K
- CTNM 86.8K
- Earning Date
- AEYE 04-29-2025
- CTNM 05-16-2025
- Dividend Yield
- AEYE N/A
- CTNM N/A
- EPS Growth
- AEYE N/A
- CTNM N/A
- EPS
- AEYE N/A
- CTNM N/A
- Revenue
- AEYE $36,851,000.00
- CTNM N/A
- Revenue This Year
- AEYE $20.29
- CTNM N/A
- Revenue Next Year
- AEYE $18.65
- CTNM N/A
- P/E Ratio
- AEYE N/A
- CTNM N/A
- Revenue Growth
- AEYE 16.52
- CTNM N/A
- 52 Week Low
- AEYE $8.91
- CTNM $3.69
- 52 Week High
- AEYE $34.85
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- AEYE 56.11
- CTNM N/A
- Support Level
- AEYE $11.17
- CTNM N/A
- Resistance Level
- AEYE $12.60
- CTNM N/A
- Average True Range (ATR)
- AEYE 1.05
- CTNM 0.00
- MACD
- AEYE 0.12
- CTNM 0.00
- Stochastic Oscillator
- AEYE 91.08
- CTNM 0.00
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.